Have you made your schedule for 2018? Take some time to consider your options and see what Ddu has planned this February!
Scientists at the National University of Science and Technology (NUST) MISIS in Russia have developed a new membrane test strip for quantitative immune chromatography rapid tests to rapidly and accurately detect an acute myocardial infarction by analysing blood for the presence of disease markers.
Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and normal tissue. As such, their main toxicity is inducing immune-mediated tissue damage.
Used medical equipment is often a smart and cost-effective way of acquiring medical device products. Everything from diagnostics to monitoring medical equipment is available online for second hand purchasing but there are a couple of things to look out for and consider when investing in these products. From first-hand experience, Drugdu.com has created a list of what to look out for and what to keep in mind.
Remote patient monitoring company LindaCare announced on Friday that they landed $8.6 million (€7 million) in Series B funding with participation by Philips, PMV, Capricorn ICT Arkiv, and Connecticut Innovations.
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
After successfully holding nineteen sessions’ exhibition, CMEH has experienced rapid development over the past years and has now become one of the largest international medical equipment fair.
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.
Artificial intelligence is gradually being adopted by health services to assist medics with the diagnosis of serious diseases. In one new development, scientists in Oxford, U.K. have launched an AI system for heart disease.
GE Healthcare and Roche have launched a partnership to assist clinicians in making better choices and help patients get individualized care.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.